Nevertheless, our data showed that inhibition of BAF155 methylation resulted in dissociation of HDAC1, and recruitment of BCL11A and PBAF to activated ISGs, implying that BAF155 methylation represents a therapeutic vulnerability for targeting the SWI/SNF complex in cancer treatment. Here, SMARCA1 is linked to cancer.